BFLY vs BIO Stock Comparison

BIO currently leads BFLY in this stock comparison, with AIQ scores of 73 vs 47. The clearest difference is value.

Market data as of Nov 18, 2026 market close· AIQ score gap 26 points
BFLY
Healthcare
vs
BIO
Healthcare
BFLY
Butterfly Network, Inc.
Price
$6.08
Day move
+5.74%
AIQ Score
47/100
Best edge
Balanced
Sector
Healthcare
BIO
Bio-Rad Laboratories, Inc.
Leads
Price
$370
Day move
+3.34%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare

What is the main difference between BFLY and BIO?

BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Butterfly Network, Inc. vs Bio-Rad Laboratories, Inc.

Data as of Nov 18, 2026· market close· Healthcare· Coverage 61/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 10/10

BIO leads

BIO leads by 26 AIQ points, primarily on Value and Risk Resilience, and the lead has widened from 20 points over 30 sessions.

Stable: 5 of 5 evidence groups support BIO, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 5 of 5Comparison trend: Strengthening
BFLY

Butterfly Network, Inc.

AIQ Score
47/100
AIQ Edge Score
4/10
BIO

Bio-Rad Laboratories, Inc.

Leads
AIQ Score
73/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors BIO over BFLY, 73 versus 47 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value and risk resilience. BIO also shows the stronger technical structure relative to its 50-day moving average. 5 of 5 covered evidence groups favor BIO today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. BIO lead: Strengthening — the AIQ differential moved from 20 to 26 points over 30 sessions. BIO leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare Butterfly Network, Inc. and Bio-Rad Laboratories, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

BFLY
-21.5%
BIO
-51.1%

Price return comparison

Growth of $10,000, price only

BFLY $7,845 · BIO $4,886

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare BFLY and BIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BFLY advantage
0
BIO advantage
  • Value29 vs 80
    BIO +51
  • Risk Resilience32 vs 74
    BIO +42
  • Momentum63 vs 79
    BIO +16
  • Quality47 vs 61
    BIO +14

5 of 5 evidence groups favor BIO. BIO’s edge is concentrated in value and risk resilience.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

BFLY+1 AIQ

Largest factor move: Momentum +2

New signals

  • Price Lost 200-Day MA — bearish, trend, long horizon
BIO0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon

BIO's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BFLY and BIO both carry a full feed there.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BIO

BIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BIO

BIO on combined revenue and EPS growth.

Value

BIO

BIO on the peer-relative Value factor, by 51 points.

Momentum

BIO

BIO on the Momentum factor, by 16 points.

Lower downside

BIO

BIO on Risk Resilience, by 42 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBFLYBIONote
Implied upside to target+91.9%—Level
Target dispersion+42.9%—Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering73Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 5 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBIO47 vs 73
FundamentalsBIOon balancerevenue growth 0% vs 0.8%; TTM ROE -6.9% vs 6%; gross margin 70.3% vs 51.3%; operating margin -49.2% vs 4.6% — BIO takes 3 of 4 decided legs, not all of them
ValuationBIOValue 29 vs 80
TechnicalsBIOPrice vs 50-day -20.8% vs -0.7%; vs 200-day -1.1% vs 15.6%
Risk ResilienceBIORisk Resilience 32 vs 74
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BFLY and BIO and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 26 points. (supports the conclusion holding)
  • 5 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

BIO lead: Strengthening — the AIQ differential moved from 20 to 26 points over 30 sessions.

Jun 1BFLY leads above the line · BIO leads belowNov 18
Today
BIO +26
47 vs 73
7 sessions ago
BIO +27
48 vs 75
30 sessions ago
BIO +20
52 vs 72
90 sessions ago
BIO +16
57 vs 73

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BFLYConflicted

1 bullish / 2 bearish / 1 neutral, conflicted

Only BFLY

  • Price Lost 200-Day MA — bearish, trend, long horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
BIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only BIO

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.

BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BFLYConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +5.74%, AIQ +1 points).

BIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BFLY closes the Value gap — currently 51 points behind, the largest single contributor to BIO's edge.
  2. 2BFLY's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it.
  3. 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

BIO leads on balance
MetricBFLYBIO
Revenue growth (YoY)0%0.8%
EPS growth (YoY)0%23.3%
Gross margin70.3%51.3%
Operating margin-49.2%4.6%
Return on equity (TTM)-6.9%6%
Debt to equity0.10.18

Performance

Split across windows
MetricBFLYBIO
1 week (5 sessions)-4.6%-4%
1 month (20 sessions)-16.1%3.6%
3 months (63 sessions)-32.6%3.1%
6 months (126 sessions)58.7%48%
Year to date60%20.9%
1 year (252 sessions)169%11.9%

Technicals

BIO has the stronger structure
MetricBFLYBIO
RSI (14)40.845.4
ADX (14)13.412.9
Price vs 50-day-20.8%-0.7%
Price vs 200-day-1.1%15.6%
Volatility (1M, annualized)106.9%31.4%

Risk

BIO is the more resilient
MetricBFLYBIO
Beta3.010.73
Sharpe ratio1.40.47
Sortino ratio2.760.69
Max drawdown-40.6%-27.2%
Current drawdown-38.8%-6.1%
Annualized volatility121.3%36.2%
Value at risk (95%)-8%-3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BFLY or BIO?

On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against BFLY's 47. The edge comes from value and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BFLY or BIO the better buy right now?

BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Stable — 5 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor BIO over BFLY?

The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 51 points; BIO leads Risk Resilience by 42 points; BIO leads Momentum by 16 points. BIO leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by BFLY simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, BFLY or BIO?

Analyst price targets imply +91.9% upside for BFLY and not covered for BIO. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BFLY or BIO?

BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 51 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BFLY or BIO?

BIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BFLY or BIO?

BIO on the Momentum factor, by 16 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BFLY or BIO?

BIO is the more resilient of the two, so the other name carries the higher downside risk. BIO on Risk Resilience, by 42 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BFLY more profitable than BIO?

The profitability evidence is mixed: gross margin 70.3% vs 51.3%; operating margin -49.2% vs 4.6%; ttm roe -6.9% vs 6%. BFLY leads on one measure and BIO on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is BIO's lead over BFLY getting stronger or weaker?

BIO lead: Strengthening — the AIQ differential moved from 20 to 26 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the BFLY vs BIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BFLY closes the Value gap — currently 51 points behind, the largest single contributor to BIO's edge; BFLY's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BFLY and BIO?

BFLY: 1 bullish / 2 bearish / 1 neutral, conflicted. BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BFLY is Golden Cross Active (bullish, long horizon). On BIO it is Golden Cross Active (bullish, long horizon).

Compare BFLY and BIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.